Podcasts about treatment strategies

How do you choose between thrombolysis, mechanical thrombectomy, or open surgery for acute limb ischemia, and what options remain when there's no vessel to open? On this episode of the BackTable Podcast, host Dr. Chris Beck is joined by vascular surgeon Dr. Anahita Dua (Massachusetts General Hospital) and interventional radiologist Dr. Ripal Gandhi (Miami Cardiac and Vascular Institute) to explore treatment strategies across the full spectrum of limb ischemia. They discuss presentation and referral patterns, the imaging and exam findings that start the clock, single-session mechanical thrombectomy, the evolving role of lysis, procedural endpoints, and deep vein arterialization for chronic limb-threatening ischemia. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported byStryker Peripheral Vascularhttps://www.stryker.com/us/en/peripheral-vascular.html --- Timestamps 00:00 - Introduction02:27 - Presentation, Referral Patterns, and Imaging06:07 - Acute Limb Ischemia: Treatment Algorithm 12:16 - Thrombectomy Device Selection16:09 - Thrombolysis and Applications Beyond Lower Extremity18:46 - Procedural Endpoints, Closure, and Case Selection24:43 - Deep Vein Arterialization: Patient Selection and Planning31:25 - DVA Technique: Imaging, Anesthesia, and Access34:58 - Step-by-Step DVA Approach 41:56 - Surveillance and Managing Expectations45:59 - Wound Care and Amputation Decisions49:40 - Future Directions in PAD52:43 - Closing Remarks --- More about this episode The conversation moves from acute interventions for the cold leg, where mechanical thrombectomy has become first-line and lysis is held in reserve, to the stepwise management of no-option chronic cases, including pedal access, valve disruption, and inflow for deep vein arterialization. Drs. Dua and Gandhi share practical insights on device selection, preventing distal embolization, and when to consider open embolectomy or hybrid approaches. The episode closes with a discussion of post-procedure surveillance, wound care, and the need for better measures of perfusion to improve limb salvage and patient outcomes. --- Resources Rutherford classification of acute and chronic limb ischemia. https://doi.org/10.1016/S0741-5214(97)70045-4 Global vascular guidelines on the management of chronic limb-threatening ischemia. Conte, Bradbury, Kolh et al., Journal of Vascular Surgery, 2019. https://doi.org/10.1016/j.jvs.2019.02.016 PROMISE II. Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemia. Shishehbor et al., New England Journal of Medicine, 2023.https://doi.org/10.1056/NEJMoa2212754 BackTable VI Episode 618, How to Manage Advanced DVA Cases: Techniques and Tips, with Dr. Kumar Madassery and Dr. Sabeen Dhand. https://www.backtable.com/shows/vi/podcasts/618/how-to-manage-advanced-dva-cases-techniques-tips --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.

When the medication you rely on for relief starts being followed by more and more headaches, it can feel confusing and frustrating.In this episode of Migraine Heroes Podcast, host Diane Ducarme explores rebound headache, also known as medication-overuse headache, and why frequent treatment can sometimes begin feeding the migraine cycle instead of calming it.You'll discover:

Aspirin or biologics? How do you choose the right treatment for AERD? On this episode of the BackTable ENT & Allergy Podcast, Dr. Basil Kahwash interviews Dr. Andrew White, Director of the AERD Clinic at Scripps Clinic, to discuss the diagnosis and management of this often underrecognized condition. They cover practical strategies for identifying AERD, the importance of a detailed NSAID history, and how treatment decisions are shaped by patient goals and disease severity. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:08 - What Is AERD and Prevalence 06:32 - History Taking and Mechanism 11:10 - Typical Symptom Progression and Alcohol Intolerance 16:41 - When to Do Aspirin Challenge 19:00 - Challenge Protocol And Upper Airway Reactions24:53 - Aspirin Desensitization vs Challenge27:58 - Aspirin therapy after desensitization and Risk of GI Bleeds31:17 - Biologics Change AERD33:42 - Choosing Aspirin Desensitization vs Biologics 35:52 - Patient Counseling and Motivational Interviewing 41:26 - Convenience and Cost of Therapy 44:10 - ENT Allergy Collaboration47:22 - Rapid Fire Pearls51:13 - Future Research & Management Direction54:05 - Final Takeaways --- More about this episode Dr. White explains that AERD affects about 8 to 10 percent of asthmatics, with even higher rates in those with severe asthma or nasal polyps. He reviews typical adult-onset progression, alcohol-related respiratory symptoms, and the underlying pathophysiology, including imbalances in arachidonic acid mediators and leukotriene surges after NSAID exposure.The conversation includes practical questions to ask when taking an NSAID history, such as reactions to common pain relievers or alcohol, and when to consider aspirin challenge. Dr. White also details long-term treatment strategies, including the role of biologics like dupilumab and aspirin therapy after desensitization, with considerations for dosing and gastrointestinal risk. He explains how factors like asthma severity, recurrent polyp disease, sense of smell, cost, and convenience all influence therapy choice. The episode concludes with a discussion of multidisciplinary collaboration, patient counseling, and Dr. White's insights on future research directions in AERD management. --- Resources Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthmahttps://pubmed.ncbi.nlm.nih.gov/16275362/ Polyphenolic Activation of Basophils Explains Alcohol Hypersensitivity in AERDhttps://pubmed.ncbi.nlm.nih.gov/41065188/ New insights into the mechanisms of aspirin-exacerbated respiratory diseasehttps://pubmed.ncbi.nlm.nih.gov/39641750/ The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunologyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7980229/ Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center studyhttps://pubmed.ncbi.nlm.nih.gov/28550988/ Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory diseasehttps://pubmed.ncbi.nlm.nih.gov/17208597/ Factors influencing aspirin therapy after desensitization (ATAD) tolerance in aspirin-exacerbated respiratory disease (AERD) patientshttps://pubmed.ncbi.nlm.nih.gov/41022281/ Feed the Good Wolf: Motivational Interviewing, Cognitive Behavioral Therapy, and Mindsethttps://pubmed.ncbi.nlm.nih.gov/42103433/ --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Jürgen Floege, MD / Richard Lafayette, MD, FACP - Strategies to Success in IgAN Management: Harmonizing the Latest Evidence and Guidance to Maximize the Potential of Foundation Treatment Strategies

Jürgen Floege, MD / Richard Lafayette, MD, FACP - Strategies to Success in IgAN Management: Harmonizing the Latest Evidence and Guidance to Maximize the Potential of Foundation Treatment Strategies

Highlights from the PER® CME activity "Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Gabriela Hobbs, MD; Rami Komrokji, MD; and Douglas A. Tremblay, MD; discuss the management of low-risk polycythemia vera (PV) based on the latest data.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/cases-and-conversations-adopting-new-treatment-strategies-in-polycythemia-vera-and-essential-thrombocythemia-fvrlThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Incyte Corporation.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

BUFFALO, NY – July 22, 2026 – A new #PrecisionOncology paper was #Published in Volume 17 of Oncotarget on July 21, 2026, titled “WIN-MTB-2024017 – WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.” The study was led by Oncotarget Editor-in-Chief, Dr. Wafik S. El-Deiry, from the Worldwide Innovative Network (WIN) Association – WIN Consortium and Legorreta Cancer Center at Brown University. Patients who develop multiple primary cancers face unique diagnostic and treatment challenges because each tumor may have distinct biological characteristics requiring different therapeutic approaches. Advances in genomic profiling and precision oncology now enable clinicians to better distinguish between independent tumors and recurrent disease while identifying molecular alterations that may guide individualized treatment strategies. This case report demonstrates how an international molecular tumor board integrated comprehensive genomic data with multidisciplinary expertise to develop personalized recommendations for a patient with an exceptionally complex cancer history. The case describes the clinical journey of a 48-year-old woman carrying a germline BRCA1 mutation who developed multiple primary cancers over nearly two decades, including breast cancer, basal cell carcinoma of the skin, high-grade serous ovarian carcinoma, colon cancer, and small bowel adenocarcinoma. During this time, she underwent multiple surgeries, chemotherapy regimens, targeted therapy with the PARP inhibitor niraparib, and extensive molecular testing to characterize each malignancy. Full press release - https://www.oncotarget.com/news/pr/international-molecular-tumor-board-explores-personalized-treatment-strategies-for-a-patient-with-multiple-primary-cancers/ DOI - https://doi.org/10.18632/oncotarget.28899 Correspondence to - Wafik S. El-Deiry - wafik_el-deiry@brown.edu Abstract video - https://www.youtube.com/watch?v=4KIDbmq6ui8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28899 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, precision oncology, molecular tumor board To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Recorded live from the American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting in Seattle, Dr. Aaron Krych joins Drs. Catherine Logan and Ashley Bassett for an in-depth discussion on the rapidly evolving field of cartilage restoration. The conversation explores how treatment has shifted from simply filling cartilage defects to restoring the entire knee joint through comprehensive patient evaluation, biologic innovations, and advanced surgical techniques.The Evolution of Cartilage RestorationWhy focal cartilage defects should be viewed as a "whole joint disease"Moving beyond isolated microfractureThe growing importance of correcting alignment, instability, and meniscal deficiencyEarlier intervention in young athletic patients to preserve long-term joint healthUnderstanding Natural HistoryWhy untreated cartilage defects can enlarge over timeRisk factors for lesion progression and development of secondary cartilage injuriesCounseling patients on long-term consequences and timing of interventionModern Treatment AlgorithmsWhy strict size-based algorithms are becoming less relevantPatient-specific factors influencing procedure selection:AgeActivity levelDefect size and locationSubchondral bone involvementPrevious surgeryOverall joint healthDiagnostic EvaluationThe expanding role of advanced MRIWhen diagnostic arthroscopy remains essentialEmerging applications of nano-arthroscopy for:Preoperative lesion evaluationAssessment of graft incorporationEvaluation of persistent postoperative symptomsSingle-Stage Cartilage Restoration TechniquesAutoCartSingle-stage autologous cartilage restorationSurgical technique pearlsCartilage harvest using GraftNet technologyPRP/BMAC augmentationTechnical considerations for successful implantationOsteochondral OptionsWhen bone involvement changes the treatment strategyIndications for:Osteochondral Autograft Transfer (OATS)Fresh Osteochondral Allograft TransplantationChoosing between autograft and allograft techniquesAlignment MattersWhy cartilage restoration cannot succeed in an overloaded compartmentIndications for combining osteotomy with cartilage restorationMedial high tibial osteotomy (HTO)Distal femoral osteotomy (DFO)Benefits of patient-specific instrumentation for osteotomy planning and executionLessons LearnedDr. Krych shares valuable experience on why successful cartilage restoration depends on more than the graft itself.Key factors influencing outcomes include:Proper patient selectionMechanical alignmentKnee stabilityMeniscal integrityPatient commitment to rehabilitationKey TakeawaysCartilage restoration has evolved from treating isolated defects to preserving the entire joint.Modern decision-making is individualized rather than based solely on defect size.Addressing alignment, instability, and meniscal deficiency is often just as important as restoring cartilage.Biologic augmentation and single-stage procedures continue to expand treatment options.Successful outcomes rely on appropriate patient selection and meticulous surgical technique.Featured GuestDr. Aaron Krych is an orthopedic sports medicine surgeon at Mayo Clinic specializing in cartilage restoration, complex knee preservation, ligament reconstruction, and sports-related injuries. His clinical expertise and research have helped shape many of today's modern cartilage restoration strategies.Subscribe to The Sports Docs Podcast for conversations with leaders in orthopedic sports medicine, surgery, injury prevention, rehabilitation, and athlete performance.www.cloganmd.comhttps://orthopedicnj.com/physicians/ashley-bassett

Access Transcript | Access Slides | Obtain Credit | For More Information    …

Dr. Goldhamer reveals why modern diets are harder to escape than addictions—and how only 2.7% of Americans meet basic health guidelines. #FoodAddiction #HealthCrisis #PleasureTrap

CME credits: 1.00 Valid until: 04-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/a-q-challengetm-replay-advancing-precision-diagnosis-and-treatment-strategies-in-acromegaly/49278/ This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnostic evaluation and treatment decision-making. The activity highlights key considerations in identifying acromegaly, interpreting clinical findings, and selecting appropriate management strategies based on patient presentation. Through guided questions and expert-informed discussion, learners gain insight into the real-world application of evidence-based approaches.=

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/moving-beyond-lid-hygiene-evidence-based-treatment-strategies/56706/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

In this episode of Better Edge, Oncologist Seth M. Pollack, MD, discusses the evolving treatment landscape for leiomyosarcoma and highlights clinical trial data recently published in The Lancet Oncology. Dr. Pollack was co-author on the study, which evaluated the combination of cabozantinib, a multitargeted tyrosine kinase inhibitor, with temozolomide in patients with refractory soft tissue sarcomas.  The conversation covers the biologic mechanisms underpinning this strategy, trial design and outcomes, and how the trial's findings compare with existing systemic therapies. The discussion also emphasizes the value of referral to specialized sarcoma centers with multidisciplinary expertise and access to subtype specific clinical trials.

Welcome to OncLive On Air®! I'm your host today, Ashling Wahner.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Marina Baretti, MD, discussed the real-world utilization of tissue-free circulating tumor DNA (ctDNA) monitoring in cholangiocarcinoma (CCA). Baretti is an assistant professor and the Jiasheng Chair in Hepato-Biliary Cancer Research at Johns Hopkins University School of Medicine, as well as co-director of the Liver and Biliary Cancer Multidisciplinary Clinic at the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. In the exclusive interview, Dr Baretti discussed multiple potential roles for ctDNA testing in CCA management, including the detection of minimal residual disease following curative-intent surgery, longitudinal monitoring of treatment response in advanced disease, and identification of emergent resistance mechanisms with targeted therapy.Baretti also reviewed findings from a small real-world observational analysis of 44 patients, in which a tissue-free ctDNA assay demonstrated high sensitivity, detecting variant allele frequencies as low as 0.2% and identifying actionable alterations in most patients; ctDNA dynamics also correlated with response and enabled early detection of resistance alterations, including secondary FGFR2 mutations, prior to radiographic progression in select cases.Lastly, Baretti contextualized these findings within the broader treatment landscape by reviewing data from the phase 2 FIGHT-202 trial (NCT02924376), which supported the FDA approval of pemigatinib (Pemazyre) in patients with previously treated CCA harboring FGFR2 fusions or rearrangements. Real-world data have confirmed the efficacy and safety of this agent observed in clinical trials, reinforcing the importance of comprehensive molecular profiling._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Lisa Salberg and Dr. Marty Maron break down new research reshaping how HCM is treated, from long-standing beta blockers to emerging targeted therapies. They also walk through arrhythmia risks, monitoring, and prevention—giving patients a clearer roadmap for managing symptoms and long-term outcomes in a rapidly changing care landscape. Conversation recorded March 13, 2026

In this podcast, experts Manish A. Shah, MD, FASCO; Syma Iqbal, MD; and Haeseong Park, MD, MPH; discuss novel combinations of targeted therapy, immunotherapy, and chemotherapy to treat resectable and unresectable gastroesophageal adenocarcinomas.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TCC865. CME/MOC/AAPA/IPCE credit will be available until January 29, 2027.Rethinking Pulmonary Fibrosis: From Fine-Tuning Diagnosis to Illuminating Novel Pathways for Emerging Treatment Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TCC865. CME/MOC/AAPA/IPCE credit will be available until January 29, 2027.Rethinking Pulmonary Fibrosis: From Fine-Tuning Diagnosis to Illuminating Novel Pathways for Emerging Treatment Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TCC865. CME/MOC/AAPA/IPCE credit will be available until January 29, 2027.Rethinking Pulmonary Fibrosis: From Fine-Tuning Diagnosis to Illuminating Novel Pathways for Emerging Treatment Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TCC865. CME/MOC/AAPA/IPCE credit will be available until January 29, 2027.Rethinking Pulmonary Fibrosis: From Fine-Tuning Diagnosis to Illuminating Novel Pathways for Emerging Treatment Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

In this episode of the Living Well podcast, host Liv Hill and guest Lyndi Mullinax, FNP delve into the complexities of Polycystic Ovarian Syndrome (PCOS). They discuss its definition, symptoms, and the importance of recognizing undiagnosed cases. The conversation highlights the four types of PCOS, with a focus on post-pill PCOS, its symptoms, and the necessary lab work for diagnosis. Lindy shares effective repair strategies and emphasizes the importance of lifestyle changes and patience in the recovery process. The episode concludes with encouragement for listeners to seek help if they suspect they have PCOS.

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Reflections on the Peter Attia/Epstein scandal; How to lower lp(a)—does diet help? What are bio-active peptides? Could they stave off kidney disease? Scientists just tested the fittest 81-year-old in the world—here's what they found; Media erroneously report that intermittent fasting is not effective for weight loss; Sugary drinks may stoke anxiety in teens; Omega-3s support kids' reading fluency and spelling scores; Surprising study shows saturated fats not harmful to kidneys.

What do the latest data from the 2025 breast cancer Winter Conference tell us? Credit available for this activity expires: 02/02/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/winter-conference-update-novel-and-emerging-treatment-2026a100030r?ecd=bdc_podcast_libsyn_mscpedu

Think beyond the esophagus. Up to 75% of eosinophilic esophagitis (EoE) patients have ENT-relevant atopic disease that is often best managed with a multidisciplinary approach. Get caught up on best practices in EoE diagnosis and treatment with this episode of the BackTable ENT Podcast, featuring dual board-certified gastroenterologist and allergist-immunologist Dr. John Leung and host Dr. Basil Kahwash. --- SYNPOSIS The discussion covers the definition, symptoms, and diagnosis of EoE, highlighting the role of food and environmental allergies. Dr. Leung and Dr. Kahwash cover diagnostic techniques like endoscopy and emerging non-invasive methods, as well as various treatment options including dietary modifications, pharmacology, and biologics. The doctors also emphasize the importance of multidisciplinary collaboration between gastroenterologists, allergists, and otolaryngologists to provide optimal care for patients with EoE. --- TIMESTAMPS 00:00 - Introduction 03:13 - Understanding Eosinophilic Esophagitis (EoE)05:45 - EoE Symptoms and Diagnosis08:41 - Role of ENT in EoE Diagnosis11:32 - Diagnostic Criteria for EoE16:34 - Treatment Options for EoE20:55 - Role of Allergists and Environmental Allergies23:24 - Pharmacological Management of EoE29:38 - Complications and Risks of EoE36:21 - Follow-Up Endoscopies and Surveillance40:34 - Future Directions in EoE Management45:21 - Conclusion and Final Thoughts --- RESOURCES Dr. John Leunghttps://www.bostonspecialists.org/dr-leung-full-profile

In this video we cover Gastric Cancer / Stomach Cancer, looking at risk factors for it as well as what are the signs and symptoms of Gastric Cancer (with Troisier's sign!). Also includes the most common locations of gastric cancer, how gastric cancer is diagnosed (including staging), and how is gastric cancer treated. PDFs available at: https://rhesusmedicine.com/pages/gastroenterologyFor more medicine videos consider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Buy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineVideo Timestamps:0:00 How common is Gastric Cancer0:10 Risk Factors for Gastric Cancer1:07 Where is Gastric Cancer most common? 1:19 Types of Gastric Cancer1:35 Most Common Site of Gastric Cancer (Which part of the stomach is most commonly affected)1:49 Signs and Symptoms of Gastric Cancer (Gastric Cancer Symptoms) 2:39 What is Troisier's Sign? (Virchows Node)2:51 Gastric Cancer Diagnosis3:10 Gastric Cancer Staging4:03 Gastric Cancer Prognosis4:35 Gastric Cancer TreatmentLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesWorld Journal of Gastroenterology, 2008. Role of symptoms in diagnosis and outcome of gastric cancer. World Journal of Gastroenterology, 14(8), pp.1149–1155. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690660/. PMCMachlowska, J., Baj, J., Sitarz, M., Maciejewski, R. & Sitarz, R., 2020. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. International Journal of Molecular Sciences, 21(11):4012. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312039/. PubMedWikipedia, 2025. Stomach carcinoma / Gastric cancer. [online] Available at: https://en.wikipedia.org/wiki/Stomach_carcinoma.ScienceDirect Topics, 2025. Stomach carcinoma – Medicine and Dentistry. [online] Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/stomach-carcinoma. ScienceDirectWorld Health Organization (WHO), 2025. Cancer fact sheet. [online] Available at: https://www.who.int/news-room/fact-sheets/detail/cancer.Disclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

In today's episode, we had the pleasure of speaking with Sarah Rutherford, MD, about the evolving role of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing for lymphoma treatment decision-making. Dr Rutherford is an associate professor of clinical medicine in the Division of Hematology/Oncology at Weill Cornell Medicine in New York, New York.  In our exclusive interview, Dr Rutherford discussed the usefulness of ctDNA for guiding patient treatment, clinical trials that are ongoing to determine the best use of this type of assay, how personalized ctDNA testing offers the potential for disease surveillance and effective intervention, key hurdles in the way of widespread implementation of ctDNA testing in clinical practice, and how integration with next-generation sequencing is expected to further tailor treatment strategies.

Did you know that the prevalence of acquired ESR1 mutations increases after exposure to endocrine therapy? Credit available for this activity expires: 11/26/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/advancing-copd-care-through-precision-medicine-and-patient-2025a1000x00?ecd=bdc_podcast_libsyn_mscpedu

Depression is not always unipolar—can you tell when bipolar features are hiding beneath the surface? Credit available for this activity expires: 11/12/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/between-lines-depression-navigating-diagnostic-nuances-2025a1000uya?ecd=bdc_podcast_libsyn_mscpedu

Episode 321 hosts Dr Rami Abadi (Dermatologist from Lebanon) This is the seventh chapter of our miniseries, 'The Beauty Of The World'. (Please also listen to episodes 102, 107, 109, 113, 118 and 224 for our other episodes and regions of the world)  In these episodes we host globally-renowned key opinion leaders to discuss their own regions beauty standards, aesthetic trends and the injectable market in their part of the world. We'll aim to understand what people find attractive, what influences this and celebrate the similarities and amazing differences amongst peoples faces and skin tones. Rami is a globally-renowned dermatologist who consults in several countries across the Middle East. We comparing Western and Middle Eastern beauty standards, and the impact of culture and social media on aesthetic preferences. Rami shares his experiences treating diverse patient demographics across Lebanon, Qatar, Dubai and even in the Ivory Coast.  00:00 Introduction  01:04 Meet Dr. Rami Abadi 02:44 Understanding Regional Beauty 05:29 Cultural and Social Influences on Beauty 06:47 Patient Profiles and Treatment Approaches 08:36 The Role of Social Media in Aesthetics  13:20 Differences in Facial Features and Treatments 15:55 Sun Exposure and Skin Care 18:01 Support Inside Aesthetics on Patreon 19:19 Regenerative Treatments and Exosomes 20:09 Patient Improvement and Polynucleotides 20:57 Exosomes: Plant vs. Human Sources 22:59 Korean Beauty Trends 24:54 Consultation and Treatment Strategies 32:29 Medical Tourism and Regional Influences 37:46 Future of Aesthetic Practices SIGN UP HERE: Alma Laser's AU workshop on 10th of November : 'The Aesthetic Playbook: How to build a business that lasts' by David Segal JOIN OUR PATREON FOR EXTRA EDUCATION & NETWORKING OPPORTUNITIES CLICK HERE TO BROWSE OUR IA OFFERS FOR DISCOUNTS & SPECIALS CLICK HERE IF YOU'RE A BRAND OR COMPANY & WANT TO WORK WITH US CLICK HERE TO APPLY TO BE A GUEST ON OUR PODCAST CONTACT US  

On this episode, we define open-angle glaucoma and describe its clinical presentations, risk factors, and underlying pathophysiolog. We evaluate current guidelines and evidence-based treatment strategies for managing open-angle glaucoma, including pharmacological and procedural interventions. We also compare and contrast the efficacy, safety profiles, and appropriate use of topical therapies and alternative options in treating open-angle glaucoma. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below: www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast.. You can get a copy of HPM at the links below: Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/ If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

In today's episode, we had the pleasure of speaking with Eunice Wang, MD, about the secondary AML treatment paradigm. Dr Wang is a professor of oncology, leader of the Leukemia Clinical Disease Team, chief of leukemia in the Department of Medicine, and an assistant member of the Tumor Immunology Program in the Department of Immunology at Roswell Park Comprehensive Cancer Center in Buffalo, New York; as well as an associate professor in the Department of Medicine and an academic scholar at the Jacobs School of Medicine and Biomedical Sciences at the State University of New York at Buffalo. In our exclusive interview, Dr Wang discussed the prevalence of secondary AML, and explained that this population lacks standard therapies, often relying on allogeneic stem cell transplantation. She noted that CPX-351, a liposomal formulation of cytarabine and daunorubicin, has generated improved outcomes compared with 7+3 chemotherapy in this population. She also highlighted future research, which includes targeted therapies and less intensive regimens.

Recurring painful bumps in your underarms, groin, or under the breasts may seem like acne – but they could be hidradenitis suppurativa (HS), a chronic, often misunderstood skin condition. HS affects up to four percent of people in the U.S., yet it’s frequently misdiagnosed or dismissed. What can those impacted do to heal and prevent these bumps? What are the misconceptions about HS? And how can patients advocate for themselves? We spoke with Vivian Shi, MD, a board-certified dermatologist, about the early warning signs of HS, treatment options ranging from topical therapies to biologics and surgery, and debunked myths linking HS to poor hygiene. We also hear from Ebone Colbert, who shares her 15-year journey with HS, from symptoms to diagnosis, and why support and the right care team matter.See omnystudio.com/listener for privacy information.

When should a parotid mass raise red flags? In this episode of the BackTable ENT podcast, Dr. Mirabelle Sajisevi, head and neck surgeon at the University of Vermont Medical Center, joins hosts Dr. Gopi Shah and Dr. Ashley Agan to discuss her approach to diagnosing and managing parotid malignancies. ---SYNPOSISDr. Sajisevi shares insights from her practice, including the importance of thorough physical exams, the utility of ultrasound and biopsy, and the intricacies of surgical planning. They also cover post-operative care, the role of radiation and chemotherapy, surveillance strategies, and the potential of emerging treatments and technologies.---RESOURCESDr. Mirabelle Sajisevi https://www.uvmhealth.org/providers/mirabelle-sajisevi-md

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.---This podcast is supported by:Ferring Pharmaceuticals https://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes.---TIMESTAMPS0:00 - Introduction1:48 - Active Surveillance in Low-Risk Prostate Cancer7:08 - Molecular Testing and Risk Stratification8:28 - Radiation Therapy Approaches20:16 - PSA Recurrence and PSMA PET Scans32:40 - The Role of ADT37:15 - PSMA PET Scans40:58 - Genetic Testing in High-Risk and Metastatic Prostate Cancer46:54 - Treatment Intensification vs. De-Intensification Trials55:59 - Castration-Resistant Prostate Cancer

In this solo episode, Dr. Tom Walters breaks down thoracic outlet syndrome (TOS)—a condition caused by compression of the nerves and blood vessels as they pass from the neck into the arm. He begins with an introduction to the condition and explains the difference between neurogenic and vascular TOS, highlighting key symptoms that require urgent medical referral. Dr. Walters then discusses how to differentiate TOS from cervical radiculopathy, a common source of confusion in clinical practice, focusing on symptom distribution, aggravating positions, and relevant clinical tests. Finally, he outlines the most effective physical therapy interventions for neurogenic TOS, including postural retraining, mobility work, scapular strengthening, breathing strategies, and activity modification. This episode is ideal for anyone interested in learning more about the anatomy, diagnosis, and rehab management of TOS, from clinicians to patients dealing with upper extremity pain and dysfunction. Rehab Science Book YouTube video References Illig KA, Donahue D, Duncan A, et al. Reporting standards of the Society for Vascular Surgery for thoracic outlet syndrome. J Vasc Surg. 2016;64(3):e23-e35. doi:10.1016/j.jvs.2016.04.039 Povlsen B, Hansson T, Povlsen SD. Treatment for thoracic outlet syndrome. Cochrane Database Syst Rev. 2014;(11):CD007218. doi:10.1002/14651858.CD007218.pub3 Gillard J, Perez-Cousin M, Hachulla E, et al. Diagnosing thoracic outlet syndrome: contribution of provocative tests, ultrasonography, electrophysiology, and helical computed tomography in 48 patients. Joint Bone Spine. 2001;68(5):416-424. doi:10.1016/S1297-319X(01)00331-2 Balci AE, Balci TA, Cakir O, et al. Surgical treatment of thoracic outlet syndrome: effect and results of surgery. Ann Thorac Surg. 2003;75(4):1091-1096. doi:10.1016/S0003-4975(02)04603-0

Genetics are foundational to much of cancer treatment, and now both the environment surrounding the tumor as well as analysis of cancer cells shed into the blood may also be used to inform treatment as well. That's according to studies … A combination of strategies help determine best cancer treatment strategies, Elizabeth Tracey reports Read More »

On this episode, we define obsessive-compulsive disorder (OCD) and describe its clinical presentations, diagnostic criteria, and underlying pathophysiology. We evaluate current guidelines and evidence-based treatment strategies for managing OCD, including pharmacologic and non-pharmacologic interventions. We also, compare and contrast the efficacy, safety profiles, and appropriate use of selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and other emerging treatment modalities for OCD.  Dr. David Osser's psychopharmacology Algorithm Website  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jacqueline Wong, MD, MSCR, FACOG For patients with endometriosis, treatment delays can profoundly impact both quality of life and clinical outcomes. Proactive strategies that address logistical barriers—such as prior authorizations—combined with education and multidisciplinary support are essential in improving care. Join Dr. Charles Turck and Dr. Jacqueline Wong as they explore practical approaches for managing this complex condition and navigating potential hurdles. Dr. Wong is a minimally invasive gynecologic surgeon and an Assistant Professor of Obstetrics and Gynecology in the School of Medicine at Oregon Health and Science University in Portland.

Episode Summary: Trapezius Myalgia – Understanding Upper Trap Pain and How to Treat It In this episode of the Rehab Science podcast, Dr. Tom Walters, DPT, breaks down one of the most common sources of neck and shoulder discomfort—trapezius myalgia. Often experienced as persistent tightness or aching in the upper trapezius muscle, this condition affects individuals who spend long periods sitting, working at a computer, or holding static postures under stress. Dr. Walters discusses the underlying anatomy and biomechanics of the trapezius, highlighting how postural overload, fatigue, and nervous system sensitization contribute to chronic discomfort. He explains why passive strategies like stretching alone may be insufficient, and emphasizes the role of progressive resistance training in improving muscle function and reducing symptoms. The episode concludes with practical movement strategies, rehab principles, and key behavioral tips for lasting relief. Resources

frequencyspecific.com   fsmsports365.com Hosts: Carolyn McMakin, MA, DC Kim Pittis, LCSP, (PHYS), MT 00:00 Introduction to Symmetry and FSM 00:25 Welcome and Introduction of Hosts 01:01 Discussing Nerve Pain and FSM Effectiveness 03:56 Exploring Current Types and Their Effects 05:31 Case Study: Treating Ovarian Cysts and Nerve Pain 10:38 Understanding Shoulder Pain and Its Origins 26:22 Biomechanics and Athletic Injuries 30:55 Complex Patient Cases and Treatment Strategies 33:31 Adrenal Support and Diurnal Rhythm 34:16 Ayurvedic Medicine and Cortisol Management 35:05 Exercise-Induced Asthma and Cortisol 35:49 Adrenal Failure and Treatment Plan 36:47 Challenges in FSM Protocols 38:28 Patient Stories and Treatment Insights 39:16 FSM Treatment Techniques and Approaches 41:10 Understanding Pain and Trigger Points 42:20 FSM in Practice: Case Studies 51:51 Collaborative Learning in FSM 55:01 Concluding Remarks and Future Sessions In the ever-evolving world of medical treatments, practitioners often find themselves grappling with complex issues like nerve pain that are unresponsive to conventional care. Frequency Specific Microcurrent (FSM) offers a breakthrough solution for these challenges, providing effective treatment options for conditions that were once deemed intractable. Below, we explore practical insights and techniques that medical practitioners can incorporate into their practice, drawn from experiences in using FSM to address nerve pain. The Challenge of Identifying Treatment Effectiveness When patients do not visibly feel the effects of FSM during treatment, it raises the question of how practitioners can ascertain if the therapy is working. Initial pain relief is an evident indicator; however, alternative markers such as improved range of motion or delayed onset of pain alleviation can also signal effectiveness. Practitioners should encourage patients to monitor their pain levels and range of motion post-treatment to evaluate its impact. Managing Expectations and Exploring Options Chronic nerve pain may not always yield immediate relief. Practitioners must advise patients that while the effects may not be instant, a progressive approach—evaluating changes over the course of hours or days—is essential. This ensures that patients understand FSM is one tool among many, aiding practitioners to pivot in treatment approaches as necessary to suit individual needs. Current Type and Frequency Decisions Not all FSM treatments are identical, with varying currents and frequencies applicable based on the patient profile. The choice between alternating and polarized positive currents can affect treatment outcomes, and starting with default protocols like alternating for non-athletes or polarized positive for athletes can be beneficial. Continuous assessment and adaptation of these settings based on patient response form an integral part of personalized FSM therapy. The Complexity and Fluidity of Pain Diagnosis Practitioners often encounter patients with multifaceted conditions where nerve pain is only one symptom. It's crucial to distinguish whether pain originates from nerve damage or other structural or musculoskeletal issues. For instance, pain labeled as nerve-related might sometimes result from facet joint issues or disc problems. Thus, thorough evaluations and applying the specific currents and frequencies designed for these conditions are vital for accurate diagnosis and effective treatment. Treatment Strategies for Recurrent and Complex Pain Those practicing FSM should also recognize that symptoms can sometimes resurface, suggesting underlying issues were not fully resolved. This necessitates a proactive approach in evaluating and adjusting treatment plans based on ongoing patient feedback and reevaluation of initial diagnoses.  Importance of Education and Continuous Learning Treating nerve pain effectively with FSM involves understanding both the body's physiology and the patient's individual experience. Continuous learning and application of FSM protocols ensure practitioners keep abreast of best practices, thus providing patients with comprehensive care.  By integrating these insights into practice, medical professionals can enhance treatment regimens involving Frequency Specific Microcurrent to manage nerve pain and related conditions, ultimately offering their patients improved quality of care and hopeful recovery outcomes.

In this episode of the Rehab Science Podcast, Dr. Tom Walters discusses proximal hamstring tendinopathy (PHT), a common condition affecting athletes, particularly runners and lifters. He explains the anatomy, biomechanics, and causes of PHT, emphasizing the importance of understanding the condition as a sensitivity issue rather than inflammation or a tear. The episode covers diagnostic strategies, effective rehabilitation techniques, and treatment options, highlighting the significance of gradual loading and physical therapy in recovery. Takeaways Proximal hamstring tendinopathy (PHT) is common among active individuals. Chronic mechanical overload is a primary cause of PHT. Symptoms often worsen with activities involving hip flexion and knee extension. Diagnosis is typically clinical and does not require imaging. Physical therapy is the cornerstone of PHT treatment. Gradual resistance training is essential for tendon healing. Rest alone will not lead to healing of tendinopathies. Education and movement-based care are crucial for recovery. PHT can be frustrating but responds well to proper rehab strategies. Most individuals can return to full activity without surgery. YouTube Link Amazon Book Link Chapters 00:00 Introduction to Proximal Hamstring Tendinopathy 02:55 Understanding the Anatomy and Biomechanics 06:09 Signs, Symptoms, and Diagnosis 08:49 Rehabilitation and Treatment Strategies 15:08 Medical Interventions and Final Thoughts

This is episode 2 of the series: Living with Lyme: Diagnosis, Treatment, and HealingEPISODE 1: Understanding and Diagnosing Lyme DiseaseLyme disease is a complex condition that can mimic many other illnesses, making accurate diagnosis difficult. This episode explores the stages of the disease, challenges in testing, and the importance of clinical judgment. Listeners will learn how to identify key symptoms, evaluate risk factors, and navigate diagnostic uncertainty to better support patient outcomes.EPISODE 2: Treatment Strategies and Support for Lyme Disease Effective treatment for Lyme disease requires a personalized, integrative approach that goes beyond antibiotics. This episode discusses complementary therapies, long-term symptom management, and the emotional toll of chronic illness. Listeners will gain strategies to manage side effects, support patient resilience, and incorporate holistic care practices in clinical settings. ---Nurses may be able to complete an accredited CE activity featuring content from this podcast and earn CE hours provided from Elite Learning by Colibri Healthcare. For more information, click hereAlready an Elite Member? Login hereLearn more about CE Podcasts from Elite Learning by Colibri HealthcareView Episode TranscriptView this podcast course on Elite LearningSeries: Living with Lyme: Diagnosis, Treatment, and Healing

Counseling patients with intermediate-risk non-muscle invasive bladder cancer can be complex, with a wide range of treatment options and care pathways. In this episode of BackTable Urology, urologic oncologists Dr. Ruchika Talwar and Dr. Kelly Bree explore how to approach this challenge with clarity and compassion. --- This podcast is supported by an educational grant from UroGen Pharma. --- SYNPOSIS They emphasize a shift toward patient-centered, less aggressive treatment strategies, highlighting the importance of quality of life in clinical decision-making. The discussion includes risk stratification, the use of intravesical gemcitabine, and ongoing clinical trials. Dr. Bree also offers actionable tips for optimizing patient preparation and recovery. This episode underscores the growing importance of listening to patient voices to shape future standards of care. --- TIMESTAMPS 00:00 - Introduction and Overview02:09 - Risk Stratification and Treatment Approaches06:12 - Intravesical Therapy Options08:47 - Quality of Life and Patient Counseling12:56 - Practical Tips for TURBT Recovery17:03 - In-Office Procedures and Patient Management21:23 - Resources and Support for Patients24:13 - Future Directions and Final Thoughts --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

In this episode of Rehab Science, Dr. Tom Walters, DPT, breaks down cervical radiculopathy—a common condition involving compression or irritation of the nerve roots in the neck. He explores the relevant cervical spine anatomy, including how disc herniations or degenerative changes like bone spurs can narrow the neural foramina and impinge nerve roots, leading to symptoms that radiate from the neck into the arm and hand. Dr. Walters reviews hallmark symptoms such as radiating pain, numbness, tingling, and muscle weakness, and discusses how these typically follow a dermatomal distribution depending on the affected cervical level. Dr. Walters also explains the clinical examination process for diagnosing cervical radiculopathy, including provocative orthopedic tests and the role of imaging like MRI when necessary. He outlines both medical and physical therapy approaches to treatment—ranging from anti-inflammatory medications and injections to targeted rehab strategies like cervical traction, neural mobilization, postural correction, and strengthening exercises. The episode wraps up with practical advice for managing this condition through movement-based rehabilitation. YouTube Video with Exercises Nerve Mobilization Exercises Amazon Book Link

Is the future of nasal polyp treatment right under our nose? In this episode of Backtable ENT, Dr. Martin Citardi, a world-renowned rhinologist and skull-based surgeon at UTHealth Houston, discusses the latest advancements in the management of nasal polyps with hosts Dr. Gopi Shah and Dr. Ashley Agan.---This podcast is supported by:Medtronic ENT---SYNPOSISDr. Citardi shares insights from his comprehensive career, spanning patient care, device, and drug development. The surgeons discuss the evolving treatment landscape, challenges in managing recurrent nasal polyps, the role of steroids and biologics, and the importance of correctly identifying the type of polyps. Additionally, Dr. Citardi emphasizes the need for a better understanding of healthcare economics, particularly concerning the high costs of new treatments. The discussion also touches on the future of research and the need for a system to deploy treatment options effectively.---TIMESTAMPS00:00 - Introduction04:39 - Nasal Polyps: Patient Presentation and Initial Examination10:25 - Detailed Examination and Endoscopy Techniques17:26 - Imaging and Lab Workup20:11 - Treatment Strategies and Patient Management31:08 - Managing Patients with Allergies, AERD, and Asthma34:09 - Biologics vs. Surgery: A Comparative Discussion42:50 - Steroid Delivery Methods and Their Effectiveness52:24 - Follow-Up, Long-Term Management and Future Research57:01 - Conclusion and Final Thoughts---RESOURCESDr. Martin Citardi's Profile:https://www.utphysicians.com/provider/martin-j-citardi/Medtronic ENT:https://www.medtronic.com/en-us/healthcare-professionals/products/ear-nose-throat

On this episode we review the 2025 Clinical Practice Guideline for the Pharmacologic Management of Adults with Dyslipidemia published by the American Association of Clinical Endocrinology. We compare and contrast the common medications used in the management of dyslipidemia and examine how these can be utilized based on the 13 updated recommendations found in the 2025 guidelines.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

On this episode, we evaluate current guidelines and evidence-based treatment strategies for managing rheumatoid arthritis. We compare and contrast the efficacy, safety profiles, and appropriate use of disease-modifying antirheumatic drugs (DMARDs), biologics, and other therapies as well as discuss patient-specific treatment strategies considering factors such as disease severity, comorbidities, and patient preferences.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com